FDA Import Alert 66-40: Check a Peptide Supplier

FDA import alert peptides: what does Alert 66-40 mean for a supplier check?

FDA Import Alert 66-40 concerns detention without physical examination of drugs from firms that have not met drug GMPs.[3] For a peptide supplier check, use FDA's general import-alert search to locate relevant alerts, then inspect the direct 66-40 record for the listed firm, address, product entry, and list status.[2][10] Document the result and seek qualified advice about a shipment.

That is a record check, not a verdict about a business. The point is to replace a loose web search, a supplier assurance, or an incomplete name match with a dated comparison of the fields FDA actually displays. Your supplier file should show what you searched, when you searched it, what the record showed, and what still needs professional review.

If you run or are starting a US research use only store, keep this task inside your supplier controls. It is separate from product selection, customer use, and clinical supply. A research use only statement does not turn a record search into a legal conclusion. The useful outcome is a clearer file for a sourcing or import decision, not a claim that a company or shipment is cleared.

Key Facts

FDA’s pages explain the alert’s scope, the search tools, and the agency review process for detained entries.[1][2][7]

• FDA says import alerts protect consumers from products with a history of known violations and can support detention without physical examination of future shipments. [1]
• FDA says its import alert databases are updated in real time and that quotation marks can help avoid loosely matched results. [2]
• FDA identifies 66-40 as a DWPE alert titled “Detention Without Physical Examination of Drugs From Firms Which Have Not Met Drug GMPs,” with a published date of September 28, 2026. [3]
• FDA says indicated drugs or drug products from foreign establishments on the 66-40 Red List may be detained without physical examination. [4]
• FDA says Yellow and Red List entries are subject to DWPE under the applicable alert, while Green List entries are exempt from DWPE under that alert. [5]
• FDA says a detained entry under 66-40 may be considered for release after responsible parties provide correction documentation for agency review. [7]

TL;DR

Start with the supplier's legal name, manufacturing address, and product description. Use quotation marks in FDA’s general import-alert search, then open the relevant alert record to compare the firm, address, product entry, and list status.[2] Save the URL, access date, search terms, and fields you compared. For a live shipment or a potential match, pause the business conclusion and obtain qualified import or regulatory advice.

What Import Alert 66-40 covers

Import Alert 66-40 covers FDA field guidance concerning drugs from foreign firms that have not met drug CGMPs. FDA labels the record a DWPE import alert and gives its full title as “Detention Without Physical Examination of Drugs From Firms Which Have Not Met Drug GMPs.” [3]

Read the alert as a document with a defined subject. Its title identifies the enforcement context; the firm and product entries identify the material you must inspect for your own comparison. Do not make the word “peptide” in a search query do the work of establishing that scope. The relevant question is what the alert actually says about the establishment and indicated products being reviewed.[3][4]

FDA says import alerts are used to protect consumers against products with a history of known violations. FDA also says it can place a product on an alert after discovering a violation and then detain future shipments without testing or physically examining them. [1] That description explains why an alert review belongs in a documented supplier process. It does not establish that every overseas supplier, every peptide related product, or every shipment has the same status.

Keep the alert’s reason separate from your supplier’s explanation. In a hypothetical review, a supplier describes a public listing as “old paperwork,” while the FDA page provides its own reason and guidance. Attribute the supplier’s comment to the supplier and retain the agency’s text separately. You have not resolved the disagreement merely by receiving an explanation. The official record and the supplier response answer different evidentiary questions.

Keep the scope equally narrow when the word peptide appears in your own catalog or sourcing notes. This article does not identify a named peptide supplier as listed or unlisted. Use the FDA record itself and your own supplier documents for the comparison. Do not use a generic internet result as a substitute for those documents.

Use a scope note at the top of your worksheet: “This review concerns the indicated firm and product information in the specified alert.” That note is especially useful when someone forwards an alert link without saying why it matters. Ask the sender which establishment or product entry prompted the concern. An alert number alone tells you where to read; it does not establish the connection to your business records.

How FDA describes detention without physical examination

Detention without physical examination describes an enforcement mechanism, not a laboratory finding about a sample in your possession.[1]

The phrase is important, but it is not a shortcut for predicting what will happen to a particular shipment. FDA's public import alert page says each alert lists the reason for the alert, affected products and firms, apparent legal or regulatory violations, and other information. [6] That means the record is structured. Your review should be structured too.

Do not write “our lot failed testing” merely because you found a possible alert entry. Such a statement would introduce an event your record check did not establish.

FDA says firms or products on a Yellow or Red List are subject to DWPE under that alert, while firms or products on a Green List are exempt from DWPE under that alert. [5] Treat those terms as alert specific labels. Do not turn a label into a universal supplier rating, and do not infer a list status from a similar name, another address, or another alert.

The difference between “subject under that alert” and a sweeping conclusion is operationally useful. Your file can state the current record field you observed. Your file should not state that you have decided the legal status of an import. A qualified import professional or regulatory counsel can assess a live transaction using facts that may not be present in a public search result. See also Top Peptides by Demand Signal: What a Five-Seller Snapshot Shows.

In a hypothetical internal exchange, a colleague asks whether a Green List reference means the supplier is generally cleared. Your answer should retain FDA’s limitation: exemption from DWPE is described under the applicable alert.[5] Ask which alert and entry the colleague is relying on before carrying the statement into a business decision. The label must stay connected to the particular record where it appears.

A second hypothetical exchange concerns a Red List entry and an urgent shipment question. Record the observed entry, then identify the question that needs qualified review: whether and how the actual transaction relates to the indicated establishment and products. Do not predict a shipment outcome from the color label alone. This distinction gives the adviser a clear starting point without presenting your screening work as an agency decision.

Prepare the supplier identity before searching

Prepare the supplier identity before searching by collecting the legal firm name, manufacturing address, and product description from your supplier records.

Do this before opening FDA's search interface. Searching first often leads to reverse fitting: you find a familiar fragment, then quietly assume it refers to the business in your file. A prepared identity record makes the comparison visible and repeatable. It also separates the manufacturer you are screening from a shipper, importer, marketplace account, or trading name that may appear elsewhere in your paperwork.

Record the legal firm name exactly as shown in the supplier's records, with any trading name in a separate note. Keep the full manufacturing address as supplied, and write the product description you are actually evaluating, using the description from the record you hold. The direct Alert 66-40 Red List contains firm and address information alongside product entries and descriptions.[10]

Also define the search date and reviewer. A simple internal line is enough: “Current FDA record checked on [date] by [role], against supplier file version [identifier].” This is a process note, not an FDA claim. It gives your team a way to repeat the check when supplier documents change or before an import related decision.

Import Alert 66-40 screening worksheet

This worksheet is deliberately cautious. “Not established from this search” is often more accurate than a confident conclusion. It tells the next reviewer that more identity evidence or professional advice is needed. It also makes clear that the worksheet is a supplier record control, not an endorsement or a legal determination.

Run an exact firm search in FDA Import Alerts

Run an exact firm search in FDA’s general Import Alerts search field, using quotation marks around the legal firm name. FDA recommends quotation marks there to reduce loosely matched results; inspection of the direct alert record is a separate step.[2]

Begin on FDA’s general Import Alerts page, whose search instructions describe exact phrases.[2] Enter the legal name from your supplier identity record and preserve the query as entered. Then open the relevant alert result and confirm the alert number and title. For this review, the direct record is Import Alert 66-40 on accessdata.fda.gov.[3] Read that page for its firm and product information; do not expect the general search field or its quotation-mark behavior to be part of the static alert page.

FDA’s Search for Import Alerts page warns that keywords are matched independently within records, so query words may appear separately rather than consecutively.[9] Preserve the page used for each search attempt. Follow the exact-phrase instruction on FDA’s general Import Alerts page for the quoted firm-name search described here.[2]

For a hypothetical search, suppose the legal name in your documents is “Example Research Materials Ltd.” Save that full quoted string as the query. If you later search only “Example Research,” record it as a separate exploratory query. Do not overwrite the original query with the shorter version after a result appears. The query history explains whether the result came from the legal name or from a broader attempt to locate a possible variant.

A missing useful result is an observation about that attempt. It does not prove that the supplier has no relevant entry. Record whether the search returned no result, returned results you could not connect to the supplier, or failed to load. Those conditions require different follow-up. A failed page request should never be logged as “no listing found,” because no completed search supports that statement.

When a result appears, open its record context before using it. A short result fragment can be a useful locator, but it is not your completed comparison. Confirm that the page reached is the intended alert, locate the relevant firm material, and move to the worksheet below. If the result leads to a different alert, retain that observation separately and seek appropriate review rather than labeling it as a result under this alert.

Exact-name FDA record check

1. Prepare the legal firm name from your supplier identity documents.

2. Open FDA’s general Import Alerts page and enter the legal firm name in quotation marks, following that page’s exact-phrase instruction.[2]

3. Open the relevant result and separately inspect the direct Import Alert 66-40 record, confirming its number and title.[3]

4. Record any broader exploratory query as a separate attempt, with its reason.

5. Compare the record entry against the supplier worksheet rather than deciding from the result fragment.

6. If a page cannot be read or an entry cannot be resolved, record that limitation and assign the follow-up.

For a hypothetical handoff, an assistant may complete the general search while another colleague performs the record comparison. The handoff should include the query and the opened result, with the comparison marked pending. Do not allow the search-complete label to advance the entire supplier review. That small distinction makes it clear whether someone actually examined the underlying record or only located a page for the next person.

Compare the firm, address, product entry, and list status

Compare the firm, address, product entry, and list status together because no one field is enough to describe an exact record match.

Begin with the firm name. Ask whether the name in your supplier record and the name shown in the FDA material are the same legal firm or merely similar text. Record the text as shown instead of normalizing it silently. If the names differ, do not fix the difference with an assumption. Put “name differs” in the worksheet and retain the documents that created the uncertainty.

Move to the address. The address comparison can strengthen or weaken a possible name match. If the record you are reviewing does not provide an address you can compare, state that directly. Do not fill the gap with country alone. The direct Alert 66-40 record supplies address information within its Red List firm entries.[10] Compare the address in the relevant entry, not a country mentioned in a search result.

Then compare the product entry. FDA says import alerts identify what products and firms are affected. [6] That is why a firm match by itself is incomplete. Preserve the product wording from both places. If the descriptions are not sufficiently comparable from the material you have, label the product comparison unresolved rather than asserting that a category word settles it.

Last, record the applicable list status shown in the current alert context. FDA explains that Yellow and Red List entries are subject to DWPE under that alert and Green List entries are exempt under that alert. [5] The phrase “under that alert” belongs in your team vocabulary. It limits the statement to the record and keeps your notes from becoming a general claim about the supplier.

Use three possible screening outcomes. A documented match means the name, address, product entry, and list context you reviewed align closely enough to raise a potential match for professional review. A documented nonmatch means one or more fields you reviewed differ in a way you can show. An unresolved result means your documents or the public record did not let you complete the comparison. These are internal screening labels, not FDA classifications.

A worked generic comparison

Suppose your supplier file contains a legal firm name, a manufacturing address, and a product description. You search the exact legal name and find text that resembles the name. Do not write “match” yet. Copy the result text. Check whether the address is the same. Check whether the product entry is the product information you are evaluating. Check the list context. If an address differs or a product entry cannot be compared, record “potential name similarity, comparison unresolved.”

That wording may feel less decisive than a supplier score. It is more useful because it leaves a clear next action. You may need corrected supplier identity documents. You may need a more specific product record. You may need qualified import or regulatory advice for an actual transaction. The wording does not accuse the supplier and does not promise that a later check will reach a particular conclusion.

Add the dated FDA record check as a source linked field in your supplier scorecard. The scorecard should retain the record URL and access date rather than reducing the check to a yes or no box. If your supply chain includes overseas manufacturing, map the legal firm and manufacturing address before screening the record. Your existing guide to sourcing peptides from China through US sellers can help keep that identity mapping separate from a marketing name.

Document the result without overstating it

Document the result as a dated FDA record observation, not as a final compliance, import, or supplier quality conclusion.

The sentence you save should identify the alert, the search terms, the record date, and the fields compared. A restrained example is: “On [access date], an exact phrase search for [legal firm name] was reviewed against FDA Import Alert 66-40. Name, address, product entry, and list status were recorded in the supplier file. This is a record screening result, not a conclusion about a shipment.” Replace the brackets with your observed data.

The file should also say what was missing. If you only had a trading name, say so. If the public material did not show an address you could compare, say so. If the product wording was too broad to compare, say so. Transparent gaps make the record more useful to counsel, an import professional, or a later internal reviewer.

FDA says the alert databases are updated in real time. [2] A practical consequence is that a saved copy should include its access date and URL. Keep the original search terms too. If a future search differs, you can distinguish a changed record from a changed query or a changed supplier document.

Use import alert screening as one documented step in your broader peptide supplier vetting checklist. Keep it separate from, but alongside, the documentation trail you use for COA lineage. A COA can support your supplier file, but it does not replace a current FDA import alert record check. For document controls, how to read a peptide certificate of analysis and how to spot a forged COA address different questions.

Do not create a supplier ranking from this one record. A listing is not a complete account of a business, and an absence from a loose search is not a clearance. A disciplined note makes the boundary explicit: “Current record reviewed, four field comparison completed to the extent shown, outside questions not decided here.”

Records to retain

Also retain the name or role of the person who performed the check and the supplier documents used for the comparison, under your normal records process, so another person can repeat the search without relying on your memory.

If you track lots or supplier files, store the alert screening date and source URL with the lot and supplier records you already track in your peptide inventory lot tracking process. This is a traceability step. It does not transform a lot record into an import authorization or a product endorsement.

Handle a potential match through the stated FDA process

Handle a potential match by preserving the record and obtaining qualified import or regulatory advice before acting on a live shipment question.

FDA's 66-40 guidance says divisions may detain, without physical examination, indicated drugs or drug products from foreign establishments on the Red List. [4] If your four field comparison raises a potential match, do not try to resolve it by changing descriptions, routing a shipment differently, or treating an incomplete web search as permission. Those actions are outside this article and outside a sound supplier record process.

FDA also describes a process for an entry detained under the alert. The agency says the owner, consignee, or another responsible party should provide documentation to the FDA Division compliance office demonstrating that CGMP violations for affected products have been adequately corrected. FDA says CDER or CVM will review that documentation to determine whether the entry may be released. [7]

Read that as a description of FDA's stated process, not as advice for your particular import. The facts of a shipment, the identity of responsible parties, and the documents available can matter. A public article cannot evaluate those facts. Your responsible next step is to preserve the record, preserve your supplier documents, and bring both to qualified counsel or an import professional.

FDA states that this import alert represents current guidance to FDA field personnel and does not create rights or bind FDA or the public. [8] That statement is another reason to avoid turning an alert page into a personal legal answer. It also supports a practical habit: record what FDA says on the date you reviewed it, then seek advice appropriate to the actual decision.

Potential match escalation rule

If all four fields appear to align with a current alert entry, pause any conclusion and preserve the current record. If one or more fields differ, preserve the nonmatch evidence and state exactly which fields differ. If a field cannot be compared, label the screening unresolved. For a prospective or detained import, use the FDA described documentation and review process as the agency states it, then obtain qualified import or regulatory advice before acting. [7][8]

This rule avoids two unhelpful extremes. It avoids treating a loose result as proof. It also avoids treating a gap as proof of safety. The decision record remains honest about what you know, what you do not know, and why another reviewer may be needed.

Build import-alert screening into supplier records

Build import-alert screening into supplier records by assigning each task an owner and defining what moves the file to the next task. Use the screen as a documented part of your process, with unresolved identity or shipment questions routed to the person qualified to address them.

The workflow below is a proposed internal design, not an FDA-mandated staffing model, schedule, or approval system. FDA supplies the public alert information and describes its agency review process.[6][7] You decide how your team collects documents and routes questions within that boundary. Make those internal choices explicit so that an administrative status cannot be mistaken for an agency determination.

Assign the work before opening a supplier file

Name an intake owner who obtains identity documents, a screening owner who performs the public-record check, and an escalation contact who can obtain qualified advice. These can be roles rather than separate employees. The point is to show which task a person is carrying out at a given moment. A purchasing contact can collect a manufacturing address without being the person who assesses a live import question.

Define what each handoff contains. Intake hands over the supplier identity packet and any missing fields. Screening hands over the comparison worksheet and unresolved observations. The escalation contact hands the relevant transaction question and supporting materials to the adviser. Do not make “sent an email” the completion condition for the entire review. An email can initiate a handoff while the substantive question remains unanswered.

For a hypothetical small team, the same person gathers the supplier documents and runs the screen, then sends a potential match to an outside professional. The record should still separate those actions. Mark intake complete when the requested identity material is available. Mark screening complete only when the worksheet describes the observations and limitations. Keep the transaction question pending until the appropriate advice is received and its scope is understood.

Use statuses that describe work

Avoid a green dashboard badge that says only “approved” when its underlying event is completion of a search. If your system requires a short label, use “screen documented” and display unresolved questions beside it. A person opening the supplier file should not have to enter a hidden notes panel to discover that the address is unknown or professional review is still pending.

Handle changed supplier information

Give a new identity document a defined place in the process. In a hypothetical update, a supplier sends a revised manufacturing address after the original screen. Do not edit the old worksheet as if that address had been available all along. Retain the earlier worksheet, attach the revised document, and create a new comparison task for the changed information. That makes the cause of the new review visible.

Start a fresh record check when a new import decision approaches.[2] This is a review trigger tied to the decision, not a universal interval prescribed by this article. Your team should know who initiates that check when the relevant decision approaches.

Distinguish an update from a clerical correction. In a hypothetical correction, your team discovers that it copied the address into the wrong supplier file. Repair the filing error and identify the affected worksheet; do not describe the incident as a change in FDA’s record. If someone already relied on the mistaken file, bring the correction to that person. The next action follows the kind of error, rather than treating every edit as a routine refresh.

Keep a queue for exceptions

An exception queue should identify the unresolved question, the material needed to address it, and the person responsible for the request. Avoid a queue that holds only supplier names. Without the question, the next reviewer cannot tell whether to seek an identity document, repeat a failed page load, or obtain professional advice about a potential match.

For a hypothetical access failure, the task can say “public record could not be read; screening owner to retry the record check.” For a hypothetical identity gap, it can say “supplier documents identify a distributor but not the manufacturing establishment; intake owner to request the manufacturing identity.” These are distinct jobs. Do not spend another round of broad searching to conceal a gap in the supplier documents.

Set follow-up timing from the actual decision you need to make. This article supplies no regulatory response deadline for your business and no promise about agency processing time. If a live transaction creates urgency, make that fact part of the question for the qualified adviser. Do not let an urgent internal due date turn an unresolved record into an assumed clearance.

Rehearse the process with fictional files

Before relying on a new worksheet, walk a colleague through hypothetical cases. Use a complete identity packet, a packet with a trading name but no established manufacturing address, and a packet whose product wording cannot be compared with the public entry. The colleague should identify a different next action for each case. If every case ends with the same completed badge, revise the internal statuses so that they preserve the differences.

Test the handoff as well as the form. Ask the colleague to retrieve the source material from the worksheet, locate the unanswered question, and identify who owns it. Do not coach them from your memory of the file. Their difficulty tells you where the record needs a clearer reference or task description. This is an administrative rehearsal with fictional material, not a test of regulatory admissibility.

When the process encounters a real exception, add a specific instruction that addresses it. If the recurring problem is filing the sales office address as the manufacturing address, add a field asking which role the supplied address represents. If the problem is treating a page failure as an empty search result, provide a separate access-failed status. Repair the step that lost the distinction instead of adding a general instruction to be more careful.

The useful end state is a supplier file that shows completed work, open questions, and the next responsible person. Keep any professional opinion attached with its limitations rather than translating it into a broader permanent supplier rating. That gives your decision owner the information needed to ask a focused follow-up while preserving the difference between internal recordkeeping and FDA’s own process.

What to do next

Move from supplier identity to a documented record comparison, then obtain qualified help for any live import question.

1. Collect the supplier's legal name, manufacturing address, and product description from its records.

2. Search the exact firm name in FDA’s general Import Alerts search, then open and inspect the current Import Alert 66-40 record.[2][3]

3. Compare any result against the address, product entry, date, and applicable list status in the record.

4. Save the record URL, access date, search terms, and matching fields in the supplier file.

5. Do not treat a name only result or a missing loose search result as a final compliance conclusion.

6. For a prospective or detained import, use the FDA described documentation process and obtain qualified import or regulatory advice before acting.

7. Repeat the record check before import decisions because FDA says the databases are updated in real time. [2]

When should you book a peptide business fit call?

Book a peptide business fit call when you need a repeatable FDA Import Alert 66-40 supplier check. Bring your supplier identity documents, the saved alert record, and the fields that remain unresolved. The conversation can focus on organizing the firm, address, and product comparison for your FDA import-alert screening workflow.

Frequently Asked Questions

What is the FDA import alert?

FDA uses import alerts for products with a history of known violations and describes detention of future shipments without testing or physical examination after a violation leads to an alert.[1] Its alert pages identify reasons, affected firms and products, apparent violations, and other information.[6] Read the applicable record before connecting that mechanism to your supplier file.

What does an FDA import alert mean?

It signals the enforcement context described in the particular alert, rather than a complete rating of a business. FDA says Yellow and Red List entries are subject to DWPE under that alert, while Green List entries are exempt under that alert.[5] Preserve that limitation when describing a search result.

What is FDA Import Alert 66-40?

FDA identifies Import Alert 66-40 as a DWPE alert for drugs from firms that have not met drug GMPs; the record reviewed here displays September 28, 2026 as its published date.[3] It is guidance to field personnel and does not create rights or bind FDA or the public.[8] Check the current record when making a new comparison.

What does FDA Import Alert 66-40 cover?

The alert guidance says indicated drugs or drug products from foreign establishments on its Red List may be detained without physical examination.[4] Compare the actual firm and product entry with your documents rather than deciding from the word “peptide.” For a shipment-specific question, preserve the comparison and obtain qualified import or regulatory advice.

Sources

Use FDA’s search guidance for the query and the direct alert record for its scope, entries, and stated review process.

1. U.S. Food and Drug Administration, Import Alerts, accessed 2026-09-30.

2. U.S. Food and Drug Administration, Import Alerts, accessed 2026-09-30.

3. U.S. Food and Drug Administration, Import Alert 66-40, accessed 2026-09-30.

4. U.S. Food and Drug Administration, Import Alert 66-40, accessed 2026-09-30.

5. U.S. Food and Drug Administration, Import Alerts, accessed 2026-09-30.

6. U.S. Food and Drug Administration, Import Alerts, accessed 2026-09-30.

7. U.S. Food and Drug Administration, Import Alert 66-40, accessed 2026-09-30.

8. U.S. Food and Drug Administration, Import Alert 66-40, accessed 2026-09-30.

9. U.S. Food and Drug Administration, Search for Import Alerts, accessed 2026-09-30.

10. U.S. Food and Drug Administration, Import Alert 66-40, Red List firm and product entries, accessed 2026-09-30.

Educational and legal disclaimer

This is educational information only. It is not legal, regulatory, tax, banking, medical, product, import, platform, or payment advice. It does not address human use or make any conclusion about a supplier, product, shipment, account, or transaction. Use qualified advisers for facts and decisions that require professional review.